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Summary 
Bariatric surgery is an effective treatment of type 2 diabetes in obese 
patients. The obesity epidemic does not spare patients with type 1 
diabetes mellitus (T1DM), but there is no consensus regarding the 
role of surgery in the management of obese T1DM patients. 
Published data consistently report significant weight loss after 
surgery in obese T1DM patients, but long-term glycaemic control 
remains difficult to achieve. Here we present our experience with a 
challenging patient and a review of the literature. 
Our patient successfully underwent a roux-en-Y gastric bypass (RYGB) 
when she was 28 years old. Five years after surgery, she was 
diagnosed with latent autoimmune diabetes of adults and insulin 
therapy was initiated. Insulin therapy proved very difficult to adjust, 
with frequent episodes of postprandial hyperglycaemia. These 
difficulties could only be overcome by the initiation of a 
subcutaneous insulin infusion using a sensor-augmented insulin 
pump with automated suspension. This change allowed better 
glycaemic control. 
Despite considerable weight loss with a concomitant decrease in 
insulin requirement, glycaemic control remained difficult after 
surgery. Due to their different impacts on glucose kinetics, the type 
of surgical operation should be part of the assessment. These 
patients might benefit from sensor-augmented insulin pump therapy 
with automated insulin suspension after bariatric surgery. The 
decision for surgical intervention in these patients should be carefully 
weighed against the difficulties in achieving adequate glycaemic 
control. 
Introduction 
The global epidemic of obesity that has developed over recent decades 
does not spare patients with type 1 diabetes mellitus (T1DM). In these 
patients, insulin resistance can accompany the deficient insulin 
secretion, and the term “double diabetes” has been suggested to 
describe this novel physiopathological entity. Moreover, a substantial 
fraction of patients suffering from type 2 diabetes (T2DM) also 
experience a progressive decline in beta-cell function of autoimmune 
origin [1]. Compared with lean individuals with type 1 diabetes, obese 
patients are at even higher risk of micro- and macro-vascular 
complications. They have a worse cardiovascular prognosis, justifying 
the requirement for tighter glycaemic control [2]. These patients 
represent a therapeutic challenge, because they require higher doses of 
insulin to achieve a good glycaemic control. This may result in further 
weight gain due to the anabolic effects of insulin, thus creating a 
vicious circle. 
A growing number of patients with T1DM are thus theoretical 
candidates for metabolic surgery, but only a small number of such 
patients have been reported in the literature. According to recent 
reviews [3, 4], the vast majority of T1DM patients undergoing 
bariatric surgery experienced significant weight loss with ensuing 
decreases in their total insulin requirements. Nevertheless, long-term 
glycaemic control remained variable and somewhat unpredictable An 
increase in the occurrence of hypoglycaemic episodes has also been 
reported [5]. Consequently, there are presently no definitive 
recommendations regarding the use and indications of bariatric 
surgery in obese T1DM patients. The aim of this article was to 
illustrate the challenges encountered in a patient who developed latent 
autoimmune diabetes of adults (LADA) several years after benefitting 
from a roux-en-Y gastric bypass (RYGB). 
Case report 
A 28-year-old woman weighing 141 kg and with a height of 167 cm 
(body mass index [BMI] 50.6 kg/m2) was referred for bariatric 
surgery. Metformin had been started 6 months before the intervention 
because of T2DM (HbA1c 7.8%, fasting plasma glucose 10 mmol/l). 
She underwent a RYGB. Metformin treatment was stopped 
postoperatively and 9 months later her HbA1c was down to 5.7% 
without treatment. Eighteen months after surgery, she had lost 57 kg, 
corresponding to 80% of excess weight loss, and thereafter her weight 
stabilised at 84 kg (BMI 30 kg/m2). At that time HbA1c was not 
measured, but fasting plasma glucose was 4.7 mmol/l. Five years after 
surgery, she experienced a further weight loss of 10 kg within 6 
months. Laboratory analyses revealed a new elevation of HbA1c 
levels to 8.6%, and the diagnosis of LADA was made on the basis of a 
strongly positive test for autoantibodies against glutamic acid 
decarboxylase (GAD) (1 390 800 IU/ml, N <10).  
The patient was diagnosed with T2DM shortly before surgery, but had 
normal blood glucose values for 5 years afterwards. A very high anti-
GAD antibody titre led to the diagnosis of autoimmune diabetes of the 
LADA type when she relapsed. Later in the course of the disease, C-
peptide was undetectable with a glycaemia of 12 mmol/l. Insulin 
therapy was initiated, with basal and prandial insulin injections, and 
she participated in an intensive insulin therapy education programme. 
In the weeks following the introduction of insulin, she began to 
experience dysphagia after eating, possibly related to the stress 
induced by the treatment. As a result, her food intake became limited, 
and she began to suffer from frequent hypoglycaemic episodes after 
prandial insulin (documented symptomatic hypoglycaemia almost 
daily, one severe episode of hypoglycaemia). In order to avoid these 
episodes, she was advised to delay the administration of prandial 
insulin until 15 minutes after the start of her meals. On this regimen, 
blood glucose control became highly erratic, with recurrent episodes 
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of postprandial hyperglycaemia (>22.2 mmol/l). Continuous glucose 
monitoring confirmed the frequent occurrence of high postprandial 
glucose peaks (fig. 1). After a couple of weeks, the patient felt more at 
ease with the injections of insulin, the stress experienced at the 
beginning of therapy decreased and food ingestion returned to normal. 
Insulin boluses were therefore moved back to the start of the meal. 
This resulted in a lowering of postprandial peaks of glycaemia. Her 
overall diabetes control, however, was still insufficient. Insulin 
boluses were therefore moved back to 15 minutes before the start of 
the meal, which resulted in a better glycaemic control: HbA1c 
decreased from 8.9 to 7.4% within 10 weeks of this change (fig. 2). 
Unfortunately, the patient remained afraid of hypoglycaemic episodes 
and could not keep to this insulin regimen. She stopped her meticulous 
glycaemic control and her HbA1c gradually rose again. Her usual 
dietary intake of carbohydrates was between 30 and 60 g per meal. 
She was advised to limit refined carbohydrates in her diet in favour of 
low glycaemic index foods, but this was insufficient to correct her 
HbA1c.  
As a result of the difficulties in optimally controlling blood glucose 
without hypoglycaemia, we decided to start continuous subcutaneous 
insulin infusion using a sensor-augmented insulin pump with 
automated insulin suspension (Minimed® 640G, Medtronic) in order 
to avoid hypoglycaemia. After the usual adaptations in the basal rate 
and boluses, overall glycaemic control improved, with an HbA1c of 
7.6% without hypoglycaemic episodes (fig. 3). Her current total 
insulin dose is 60 IU/d (0.6 IU/kg/d) divided into 36 IU/d of basal 
insulin and 24 IU/d of bolus insulin. Her carbohydrate-to-insulin ratio 
is between 10 and 15 g/IU. Combination boluses are administrated 15 
minutes before each meal. As can be seen in figure 4, during a day of 
fast the basal rate was not the main problem for treatment adjustment. 




Figure 1: Continuous monitoring of blood glucose (mmol/l) with multiple-dose insulin injections and prandial insulin administered 15 minutes after the start of meals. Solid lines 
represent the record of six individuals and consecutive days. The dotted line is the average of the six recorded days. The shaded zone represents the target glucose value. 
 
 
Figure 2: Continuous monitoring of blood glucose (mmol/l) with multiple-dose insulin injections and prandial insulin administered 15 minutes before the start of meals. Solid 
lines represent the record of six individuals and consecutive days. The dotted line is the average of the six recorded days. The shaded zone represents the target glucose value. 
 
 
Figure 3: Continuous glucose monitoring with continuous subcutaneous insulin infusion via a sensor-augmented insulin pump with automated insulin suspension. Insulin boluses 
administered 15 minutes before the start of the meals. Solid lines represent the record of six individuals and consecutive days. The dotted line is the average of the six recorded 
days. The shaded zone represents the target glucose value. 
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Figure 4: Continuous glucose monitoring during a day of fasting and pump therapy. Plus sign = calibration; inverted triangle = ALERT. 
 
Discussion 
The patient described here illustrates the challenges faced by T1DM 
patients after RYGB surgery. Indeed, although weight outcomes after 
bariatric surgery are similar in patients with type 1 and type 2 diabetes 
[6, 7], glycaemic control may not necessarily improve in T1DM. This 
discrepancy may at least partially result from an increased variability 
in postprandial blood glucose concentrations after RYGB, combining 
marked hyperglycaemic peaks very early after meal ingestion with 
subsequent rapid decreases in glycaemia. Such variability can become 
problematic for adequate glycaemic control when patients who remain 
insulin dependent use multiple injections. 
This evolution in the postprandial glycaemic profile after bariatric 
surgery is the consequence of the faster delivery of sugars to the 
jejunum. Jimenez et al. [8] reported the glucose response to a 
standardised mixed meal challenge after either RYGB or sleeve 
gastrectomy in 31 subjects who had remission of T2DM. After RYGB 
they found rapid increases in plasma glucose, with mean glucose 
peaks of 12 mmol/l occurring 33 minutes after the start of a meal. 
These peaks were followed by a pronounced fall in glycaemia (6.7 
mmol/l) occurring 60 minutes thereafter. In the sleeve gastrectomy 
group, the mixed meal produced a lower glucose peak (8.9 mmol/l) 
and, importantly, a longer time to glucose peak (47 minutes) with a 
smaller subsequent glucose decline (3.5 mmol/l) in the 60 minutes 
after the peak. The large excursions in glucose concentrations reported 
after RYGB result in a dissociation between the rate of glucose 
absorption and the kinetics of insulin secretion. This dissociation may 
account for the difficulties encountered in the treatment of T1DM 
after this procedure. When considering glucose absorption, sleeve 
gastrectomy could be considered a more physiological and predictable 
intervention in terms of glucose absorption and thus may constitute a 
better solution for glucose control in T1DM. However, this 
hypothesis, also advocated by some authors [9], is awaiting definitive 
demonstration. 
Published data regarding glycaemic control in patients with T1DM 
after obesity surgery are somewhat conflicting, possibly because of 
wide variations between diabetes therapies. Czupryniak et al. [10] 
were the first to report significant reductions in either insulin need or 
HbA1c after gastric bypass in three obese patients with poorly 
controlled T1DM before surgery. These data, however, are difficult to 
interpret, since C-peptide levels were not reported and treatment 
modalities were not indicated. In contrast, Chuang and al. [5] reported 
that HbA1c significantly worsened and hypoglycaemic episodes 
became more frequent after RYGB in two adolescents with T1DM. 
This occurred despite significant weight loss and improvements in 
cardiovascular risk factors such as dyslipidaemia or obstructive sleep 
apnoea. As in our patient, these two adolescents took insulin boluses 
postprandially because of the occurrence of gastrointestinal 
symptoms. Under such a regimen, a postprandial glucose peak cannot 
be avoided, because of the modification in glucose absorption 
described above. As a result, insulin is still acting when glucose levels 
are decreasing, creating a risk for hypoglycaemia. 
In a larger study [11] reporting the evolution of ten patients 
undergoing various surgical procedures (RYGB, sleeve gastrectomy 
and adjustable gastric banding), nine achieved a significant excess 
weight loss (averaging 60%), but none could attain optimal glucose 
control. Their average HbA1c went from 10% before to 8.9% after the 
surgery. However, since neither the modality of diabetes treatment nor 
the surgical procedure were precisely reported, it is impossible to 
draw meaningful conclusions from these data. In another study [12], 
including 13 patients with T1DM who underwent RYGB or sleeve 
gastrectomy, the median postoperative decrease in HbA1c was 0.7% 
at 12 months, with great heterogeneity between individuals and an 
increase in minor hypoglycaemia. This heterogeneity in glucose 
control may be explained by the fact that two different surgical 
operations were performed in this study. In addition, data at 1 year 
could be biased because food intake is sometimes still irregular at this 
point. Consistent increases in HbA1c levels have been reported at 5 
years [13]. A recent study by Vilarrasa et al. [14] of 32 patients with 
T1DM who underwent various surgical procedures (RYGB, sleeve 
gastrectomy or duodenal switch) confirmed the benefits of surgery on 
insulin requirement. This study also demonstrated that despite an 
initial decrease in HbA1c observed during the first year after surgery, 
the metabolic control was not sustained in the longer term. 
In T1DM, short-acting insulin boluses before meals are associated 
with better glycaemic profiles than postprandial administration, and 
this could also be true after RYGB because of the faster glucose 
absorption. This hypothesis is in accordance with our present 
observation, where the best glycaemic control in the period preceding 
introduction of the sensor-augmented insulin pump was achieved with 
preprandial insulin boluses. However, this multiple daily injection 
regimen was also accompanied by an increased occurrence of 
hypoglycaemia. 
In this respect, sensor-augmented insulin pump therapy with 
automated insulin suspension may constitute the treatment of choice 
for T1DM patients undergoing obesity surgery. In a report of three 
patients undergoing RYGB [15], two patients on an insulin pump 
(without sensor) remained stable after the surgery whereas the third 
patient, who used multiple daily injections, experienced a worsening 
of HbA1c levels. Nevertheless, achieving adequate glycaemic control 
remains challenging in these patients. In that study, insulin 
requirements were significantly decreased in all three patients after 
weight loss, but diabetes control remained inadequate in all three of 
them. A similar observation was made by Blanco et al. [6] in two 
T1DM patients who were started on an insulin pump because of 
insufficient glycaemic control with multiple daily injections. 
There is currently no recommendation regarding the use of bariatric 
surgery in obese patients with T1DM. However, the bulk of existing 
data suggests that glycaemic control in these patients is at least not 
improved, and possibly rendered more difficult, by the intervention, 
although total daily insulin requirement is decreased. In some cases, a 
pancreatic transplant was eventually needed [16]. This suggests that a 
careful preoperative evaluation for specific types of diabetes mellitus 
is mandatory before proceeding with bariatric surgery. Failure to do so 
may have very deleterious consequences for patients misdiagnosed 
preoperatively with T2DM: a worsening of their HbA1c levels after 
surgery can lead to reclassification of their diabetes as LADA [7, 17]. 
In conclusion, the marked and sustained weight loss consistently 
observed after bariatric surgery is not sufficient to expect improved 
glycaemic control in T1DM. In the absence of residual beta-cell 
function, reaching optimal glycaemic control remains challenging 
because of the complex kinetics of postprandial glucose absorption 
after RYGB. For T1DM patients after bariatric surgery, we suggest 
that multiple daily injections of insulin should be replaced by sensor-
augmented insulin pump therapy with automated insulin suspension to 
avoid postprandial hypoglycaemia. Moreover, preprandial insulin 
boluses should be carefully timed to limit glucose peaks and reduce 
the risk of postprandial hypoglycaemia. Nevertheless, more work is 
needed in order to better delineate both the most appropriate type of 
intervention as well as the best treatment regimen of type 1 diabetes 
after bariatric surgery. 
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